View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
April 27, 2011

MonoSol and KemPharm Partner to Develop ADHD Drug

PharmFilm drug delivery technology developer MonoSol Rx has announced a partnership with biopharmaceutical company KemPharm to develop new, safer therapies for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and cardiovascular disease. The drug development part

By cms admin

PharmFilm drug delivery technology developer MonoSol Rx has announced a partnership with biopharmaceutical company KemPharm to develop new, safer therapies for the treatment of attention deficit hyperactivity disorder (ADHD), pain, and cardiovascular disease.

The drug development partnership will combine MonoSol Rx’s patent-protected pharmaceutical film technology with KemPharm’s unique ADHD compound KP106 for the first time to provide improved therapy for ADHD patients.

KP106 is composed of d-amphetamine and a ligand. A Phase I human clinical trial demonstrated KP106 to be a safe and effective treatment option for ADHD.

The study reported that patients receiving KP106 experienced decreased side effects and risk of abuse, and also proved to be more effective against ADHD.

MonoSol Rx which will have a financial stake in KP106 will manufacture and be eligible for development milestone payments.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU